Equipoise (Boldenone Undecylenate) — Dosing, Cycles, Half-Life & Side Effects
Equipoise (Boldenone Undecylenate) is an injectable anabolic-androgenic steroid with a half-life of 14 days. Long-acting injectable for lean mass and increased appetite with moderate anabolic effects. Primary risks include strong HPTA suppression. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.
Quick Facts
| Class | Injectables |
|---|---|
| Half-life | 14 days |
| Detection window | 150 days |
| Aromatization | Mild |
| Hepatotoxicity | Low |
| Suppression | 7/10 |
| 17α-alkylated | No |
| Administration | injectable |
Typical Dosing Ranges
Common dose range: 300-600mg/week
Cycle length: 12-16 weeks
Time to steady state: ~70 days
Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.
Stacking Considerations
- No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.
PCT Requirements
- This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
- Depot clearance estimate: ~70 days post-last-dose before SERM start (5 × apparent depot half-life of 336h).
- Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
- Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.
Side Effect Profile
- Increases RBC/HCT
- Anxiety in some users
- Long detection time
- Requires longer cycles
Known Interactions
No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry. Browse the full interaction matrix to cross-reference manually.
Related compounds
Monitoring (Bloodwork & Vitals)
- Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
- Lipid panel (total cholesterol, HDL, LDL, triglycerides)
- CBC (hemoglobin, hematocrit — watch for erythrocytosis)
- Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
- Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)
Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.
Frequently Asked Questions
What is the half-life of Equipoise (Boldenone Undecylenate)?
Equipoise (Boldenone Undecylenate) has a half-life of approximately 14 days. Clearance estimate: 336h � 5 = 1680h = 70 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.
What is the typical dose range for Equipoise (Boldenone Undecylenate)?
Commonly reported ranges for Equipoise (Boldenone Undecylenate): 300-600mg/week. Cycle length: 12-16 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.
Does Equipoise (Boldenone Undecylenate) suppress natural testosterone?
Equipoise (Boldenone Undecylenate) causes strong suppression of the HPTA axis (score 7/10). Post-cycle therapy (PCT) is recommended after use.
Is Equipoise (Boldenone Undecylenate) liver toxic?
Hepatotoxicity rating: Low. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.
Does Equipoise (Boldenone Undecylenate) aromatize to estrogen?
Aromatization profile: Mild. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.
What is Equipoise (Boldenone Undecylenate) typically used for?
Equipoise (Boldenone Undecylenate) is commonly used for: Lean bulking, Endurance, Cutting. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.
Citations
- Ester chemistry extrapolation. 2004. Veterinary pharmacology reference — Half-life approximately 14 days estimated from undecylenate ester chain length; no human PK study (evidence grade C)
- Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
- Minto CF et al.. 1997. J Clin Endocrinol Metab — Boldenone undecylenate ester-chain extrapolation — undecylenate ester produces ~14-day half-life based on ester-class PK; veterinary formulation (Equipoise) used as injectable
- Hartgens F, Kuipers H. 2004. Sports Medicine — Boldenone moderately suppresses HPT axis; less than testosterone but more than oxandrolone; supports suppressionScore 7/10
- Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem. 2003;40(Pt 4):321-56. PMID: 12880534
Disclaimer
StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Equipoise (Boldenone Undecylenate). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.